amoxicillin-clavulanate + ceftriaxone

This antibiotic regimen consists of the sequential administration of amoxicillin-clavulanate and ceftriaxone, specifically evaluated in clinical trials led by Alejandro Hoberman for the nonsurgical management of recurrent acute otitis media (AOM) in children. Amoxicillin-clavulanate is an oral antibacterial combination consisting of a penicillin-class antibiotic and a beta-lactamase inhibitor, while ceftriaxone is a long-acting, broad-spectrum, third-generation cephalosporin administered intramuscularly. The regimen follows a stepwise approach where amoxicillin-clavulanate is the first-line treatment, with ceftriaxone reserved for cases with an inadequate clinical response. Both agents function by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs), effectively targeting common otitis pathogens such as *Streptococcus pneumoniae*, *Haemophilus influenzae*, and *Moraxella catarrhalis*.

Brand names

AugmentinRocephin

Other names

amoxicillin-potassium clavulanateceftriaxone sodiumamoxicillin-clavulanate and/or ceftriaxone